166 related articles for article (PubMed ID: 32957385)
1. Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [223Ra]RaCl2 therapy.
Sraieb M; Hirmas N; Conrad R; Marinova M; Essler M; Herrmann K; Ahmadzadehfar H
Medicine (Baltimore); 2020 Sep; 99(38):e22287. PubMed ID: 32957385
[TBL] [Abstract][Full Text] [Related]
2.
Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
[TBL] [Abstract][Full Text] [Related]
3. Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Agostini S; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2633-2638. PubMed ID: 32249345
[TBL] [Abstract][Full Text] [Related]
4. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
7. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
8. Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice.
Dizdarevic S; McCready R; Vinjamuri S
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):192-217. PubMed ID: 31471713
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
Kuppen MC; Westgeest HM; van der Doelen MJ; van den Eertwegh AJ; Coenen JL; Aben KK; van den Bergh AC; Bergman AM; den Bosch JV; Celik F; Hendriks MP; Lavalaye J; der Meer SV; Polee MB; Somford DM; van Oort IM; Uyl-de Groot CA; Gerritsen WR
Future Oncol; 2020 Jul; 16(19):1371-1384. PubMed ID: 32469606
[No Abstract] [Full Text] [Related]
10. The Prognostic Value of Quantitative Bone SPECT/CT Before
Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
[TBL] [Abstract][Full Text] [Related]
11. The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study).
Bauckneht M; Rebuzzi SE; Signori A; Frantellizzi V; Murianni V; Lodi Rizzini E; Mascia M; Lavelli V; Donegani MI; Ponzano M; Gaudiano A; Stazza ML; Licari M; Cavallini L; Laghi V; Cindolo L; Maggi M; Sciarra A; Mammucci P; Sambuceti G; Costa RP; Spanu A; Rubini G; Monari F; De Vincentis G; Fornarini G
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1063-1074. PubMed ID: 34486070
[TBL] [Abstract][Full Text] [Related]
12. Review of Palliative
Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
[TBL] [Abstract][Full Text] [Related]
13. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
15. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
17. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
19.
Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
[TBL] [Abstract][Full Text] [Related]
20. Dose estimation after a mixed field exposure: Radium-223 and intensity modulated radiotherapy.
Bastiani I; McMahon SJ; Turner P; Redmond KM; McGarry CK; Cole A; O'Sullivan JM; Prise KM; Ainsbury L; Anderson R
Nucl Med Biol; 2022; 106-107():10-20. PubMed ID: 34968973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
